Reokklusionsprophylaxe im Kindesalter

Sabine Becker; Christine Heller; Elisabeth Lenz; W. Kreuz

doi:10.1055/s-0038-1656661

Hämostaseologie, Table of Contents

Hamostaseologie 1996; 16(04): 220-226
DOI: 10.1055/s-0038-1656661

Übersichtsarbeiten/Review Articles

Schattauer GmbH

Reokklusionsprophylaxe im Kindesalter

Sabine Becker

¹Klinikum der Johann-Wolfgang-Goethe-Universität, Zentrum der Kinderheilkunde und Jugendmedizin, Klinik für Kinderheilkunde III - Pädiatrische Hämatologie und Onkologie (Leiter: Prof. B. Kornhuber), Frankfurt a. M.

,

Christine Heller

¹Klinikum der Johann-Wolfgang-Goethe-Universität, Zentrum der Kinderheilkunde und Jugendmedizin, Klinik für Kinderheilkunde III - Pädiatrische Hämatologie und Onkologie (Leiter: Prof. B. Kornhuber), Frankfurt a. M.

,

Elisabeth Lenz

²Universitätskinderklinik Göttingen

,

W. Kreuz

¹Klinikum der Johann-Wolfgang-Goethe-Universität, Zentrum der Kinderheilkunde und Jugendmedizin, Klinik für Kinderheilkunde III - Pädiatrische Hämatologie und Onkologie (Leiter: Prof. B. Kornhuber), Frankfurt a. M.

› Author Affiliations

Abstract

PDF Download

Zuammenfassung

Für eine erfolgreiche Lysetherapie bei venösen und arteriellen thrombotischen Verschlüssen ist eine Reokklusionsprophylaxe essentiell. Dabei ist ein möglichst frühzeitiger Beginn - parallel zur Lysetherapie - wichtig. Als Adjuvans zu den Fibrinolytika werden bei Erwachsenen neben unfraktioniertem Heparin auch niedermolekulare Heparine (LMWH) eingesetzt; letztere scheinen zumindest gleich wirksam bei etwas geringerem Blutungs- und Nebenwirkungsrisiko. Nach venösen Thrombosen im Kindesalter werden zur Langzeitprophylaxe Cumarinderivate eingesetzt. Bei Kontraindikationen für Cumarin könnten sich niedermolekulare Heparine (LMWH) in Zukunft als vielversprechende Alterna-tiven auch für pädiatrische Patienten erweisen. Allerdings gibt es noch keine Daten zum Osteoporoserisiko unter Langzeitgabe von LMWH; speziell im Kindesalter sollten Nutzen und Risiken für diese Substanzen sorgfältig abgewogen werden. Die Reokklusionsprophylaxe arterieller Gefäße stellt eine Indikation in erster Linie für Azetylsalizylsäure neben unfraktioniertem Heparin und LMWH dar. Im Gegensatz zum Erwachsenenalter werden bei Kindern alle Dosierungen an das Körpergewicht oder die Körperoberfläche angepaßt.

Schlüsselwörter

Thrombose - Reokklusion - Prophylaxe - Kinder

PDF (13374 kb)

References

LITERATUR
1 Agnelli G, Pascucci C, Cosmi B, Nenci GG. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits. Thromb Haemost 1990; 63: 204-7.
2 Albers GW. Antithrombotic agents in cerebral ischemia. Am J Cardiol 1995; 75: 34-B-38B.
3 Anderson DR, Brill Edwards P, Walker IR. Warfarin-induced skin necrosis in two patients with protein S deficiency; successful reinstatement of warfarin therapy. Blood 1989; 74 Suppl 409
4 Andrew M, Michele D, Magaret A. et al. Venous thromboembolic complications (VTE) in children: first analysis of the Canadian Registry of VTE. Blood 1994; 83: 1251-7.
5 Andrew M, Schmidt B. Use of heparin in newborn infants. Semin Thromb Hemost 1988; 14: 28-32.
6 Antman EM. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation 1994; 90: 1624-30.
7 Barrowcliff TW, Curtis AD, Tomlinson TP. et al. Standardization of low molecular weight heparins: A collaborative study. Thromb Haemost 1985; 54: 675-9.
8 Beeser H. Überwachung der Behandlung mit Cumarinderivaten. In: Thrombophilie und Antikoagulation. XXXVI. Hamburger Symposium über Blutgerinnung am 11. + 12.6.1993. Tilsner V, Matthias F. (Hrsg). Edition Roche 1994; 103-17.
9 Bengtsson-Olivecrona G, Olivecrona T. Binding of active and inactive forms of lipoproteinlipase to heparin. Biochem J 1985; 226: 406-8.
10 Bjornsson TO, Wolfram BS, Kitchell BB. Heparin kinetics determined by three assay methods. Clin Pharmacol Ther 1982; 31: 104-13.
11 Boss JM, Summerly R. Prevention of warfarin-induced skin necrosis. Br J Dermatol 1979; 100: 617-20.
12 Breddin HK, Grun H, Krzywanek HJ, Schremmer WP. Zur Messung der »spontanen« Thrombozytenaggregation. Plättchen-aggregationstest III. Methodik Klin Wo-chenschr 1975; 53: 81-9.
13 Broekmans AW, Bertina RM, Loelinger EA. et al. Protein C and the development of skin necrosis during anticoagulant therapy. Thromb Haemost 1983; 49: 251-55.
14 Chong BH, Berndt MC. Heparin-induced thrombocytopenia. Blut 1989; 58: 53-7.
15 Coller B. Platelets and thrombolytic therapy. N Engl J Med 1990; 322: 33-42.
16 Eisenberg PR. Mechanisms of reocclusions after coronary thrombolysis. Z Kardiol 1993; 82 (Suppl. 02) 175-8.
17 Eisenberg PR, Sherman LA, Jaffe AS. Paradoxic elevation of fibrinopeptide A: evidence for continued trombosis despite intensive fibrinolysis. J Am Coll Cardiol 1987; 10: 527-9.
18 Eisenberg PR, Sherman LA, Rich M. et al. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. J Am Coll Cardiol 1986; 7: 1255-62.
19 Eisenberg PR, Sobel BE, Jaffe AS. Activation of prothrombin accompanying thrombolysis with rt-PA. J Am Coll Cardiol 1992; 19: 1065-9.
20 Ginsberg JS, Kowalchuk G, Hirsh J. Heparin effect on bone density. Thromb Haemost 1990; 64: 286-9.
21 Greinacher A, Eichler P. Die Heparin-assoziierte Thrombozytopenie - Immunologische Aspekte. Hämostaseologie 1995; 15: 117-21.
22 Gruber A, Harker LA, Hanson SR. et al. Antithrombotic effects of combining activated protein C and urokinase in nonhuman primates. Circulation 1991; 84: 2454-62.
23 Gulba DC, Westhoff-Bleck M, Jost S. et al. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Circulation 1991; 83: 937-44.
24 Harenberg J. Pharmacology of low molecular weight heparins. Semin Thromb Hemost 1990; 16 Suppl 12-8.
25 Harenberg J, Giese CH, Dempfle CE. et al. Biological activity and safety of the subcutaneous administration of high doses of low molecular weight heparin for 8 days in human volunteers. Thromb Haemost 1989; 61: 357-62.
26 Harenberg J, Giese CH, Knödler A. et al. Neutralization of a low molecular weight heparin Kabi 2165 by protamine chloride. Klin Wochenschr 1986; 64: 1171-5.
27 Harenberg J, Gnasso HA, De Vries JX. et al. Inhibition of low molecular weight heparin by protamin chlorid in vivo. Thromb Res 1985; 38: 11-20.
28 Harenberg J, Roebruck P, Heene DL. and the HESIM-Group. Subcutaneous low molecular mass heparin (1mm) against un-fractionated (UF) heparin for prophylaxis of thromboembolism in medical patients. Ann Hematol 1994; 69 (Suppl II) A55 Abstr. 51
29 Harenberg J, Leber G, Dempfle CE. et al. Long term anticoagulation with low molecular weight heparin in outpatients with side effects on oral anticoagulants. Nouc Rev Franc Hematol 1989; 31: 363-9.
30 Harker LA. Antithrombotic strategies for resistant thrombo-occlusive events. Biomedical progress 1995; 8: 17-27.
31 Harker LA, Gent M. Antiplatelet agents in the management of thrombotic disorders. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practise. . Colman RW. et al. (eds). Philadelphia: JB Lippincott; 1994: 1506
32 Harker LA, Maraganore JM, Hirsh J. Novel antithrombotic agents. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practise. Colman RA. et al. (eds). Philadelphia: JB Lippincott; 1994: 1651
33 Hass WK, Easton JD, Adams HP. et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high risk patients. N Engl J Med 1989; 321: 501-7.
34 Hirsh J, Buchanan MR. Comparative effects of heparin and LMW heparin on hemostasis. Thromb Res Suppl 1991; 14: 11-7.
35 Holmer E, Kurachi K, Söderström G. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor XIa, factor Xlla and kallikrein by antithrombin. Biochem J 1981; 395: 400-7.
36 Hull R, Hirsh J, Jay R. et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982; 307: 1676-81.
37 Hull RD, Raskob GE, Pineo GF. et al. Subcutaneous low-molecular-weight-hepa-rin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-82.
38 Kakkar VV. An international multicentre trial. Prevention of fatal postopertive pulmonary embolism by low doses of heparin. Lancet 1975; I: 45-51.
39 Kreuz W, Heller C, Lenz E. Thrombolyse mit rt-PA im Kindesalter - eine Übersicht. Fibrinolyse 1996; 1/2: 4-10.
40 Lechler E, Schramm W, Flosbach SW. and The Prime-Study-Group. A randomized double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised medical patients. Ann Hematol 1994; 69 (Suppl II) A55 Abstr. 52
41 Leiber G, Egbrink R. Zur Therapie der »Cumarinnekrose«. Internist 1972; 13: 340-3.
42 Leizorovicz A, Simmoneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep vein thrombosis: a meta-analysis. Br Med J 1994; 309: 299-304.
43 Lensing AWA, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 1995; 155: 601-7.
44 Lenz E, Heller C, Schröter W, Kreuz W. Reocclusion prophylaxis after venous thrombosis or arterial thromboembolic event in children. Ann Hematol 1996; 72 (Suppl I) A64
45 Loeliger EA. ICSH/ISTH recommendations for reporting prothrombin time in oral anticoagulant control. Thromb Haemost 1985; 53: 155-7.
46 Loeliger EA, Van Den Besselaar AMHP. Thromboplastin Calibration and Oral Anticoagulant Control. Boston, The Hague, Dordrecht, Lancaster: Martin Nijhoff Publishers 1984; 2-9.
47 Magnani HN. Heparin-induced thrombocytopenia: an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 1993; 70: 554-61.
48 Marbert GA, Duckert F. The development of thrombolytic treatment in venous thrombosis. Experience with streptokinase-based regimens. Vasa 1986; 15: 359
49 Massonnet-Castel S, Pelissier E, Bara L. et al. Partial reversal of low-molecular-weight heparin (PK 10169) Anti Xa Activity by protamine sulfate: In vitro and in vivo study during cardiac surgery with extracorporal circulation. Haemostasis 1986; 16: 139-45.
50 Mc Donald MM, Jacobson LJ, Hay WW, Hathaway WE. Heparin clearance in the newborn. Ped Res 1981; 15: 1015-8.
51 McGehee WG, Klotz TA, Epstein DJ, Rapaport S. l. Coumarin necrosis associated with hereditary protein C deficiency. Ann Intern Med 1984; 100: 59-63.
52 Melissari E, Paker CJ, Wilson NV. et al. Use of low molecular weight heparin in pregnancy. Thromb Haemost 1992; 68: 652-6.
53 Minar E, Ehringer H, Hirschl M. Trans-aminasenanstiege: eine weitgehend unbekannte Nebenwirkung der Heparintherapie. Dtsch Med Wochenschr 1980; 105: 1713-4.
54 Monreal M, Lafoz E, Olive A. et al. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin®) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994; 71: 7-11.
55 Neuhaus KL, von Essen R, Tebbe U. et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK). Circulation 1994; 90: 1638-42.
56 Okajma Y, Kayama S, Maeda Y. et al. Studies on the neutralizing mechanism of antithrombin activity of heparin by protamine. Thromb Res 1981; 24: 21-9.
57 O' Reilly RA. Warfarin metabolism and drug-drug interaction. In: The New Dimensions of Warfarin Prophylaxis. . Wessler S, Becker CG, Nemerson Y. (eds). Volume 214 of Advances in Experimental Medicine and Biology. New York: Plenum; 1986: 205-12
58 Pineo GF, Hull RD, Rosenbloom D. et al. A cost-effectiveness analysis using actual costs of low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. Int Angiology 1994; 13 (Suppl.I) Abstr 87
59 Rapold HJ. Promotion of thrombin activity by thrombolytic therapy without simultaneous anticoagulation. Lancet 1990; 1: 481-2.
60 Rapold HJ, Weiss M, Baur H, Haeberli A. Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue type plasminogen activator. Circulation 1989; 79: 980-9.
61 Rasche H. Heparine: Abhängigkeit der Wirkung von Antithrombin, Molekulargewicht und Dosis. In: Thrombophilie und Antiko-agulation. XXXVI. Hamburger Symposium über Blutgerinnung am 11. + 12.6.1993. Tilsner V, Matthias F. (Hrsg). Edition Roche 1994; 23-32.
62 Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. J Clin Invest 1975; 56: 624-8.
63 Schmidt B, Buchanan MR, Ofosu F. et al. Antithrombotic properties of heparin in a neonatal piglet model of thrombin-induced thrombosis. Thromb Haemost 1988; 60: 289-92.
64 Schmidt B, Mitchell L, Ofosu F. et al. Standard assays underestimate the concentration of heparin in neonatal plasma. J Lab Clin Med 1988; 112: 641-3.
65 Schmidt B, Ofosu A, Mitchell L. et al. Anticoagulant effects of heparin in neonatal plasma. Pediatr Res 1989; 25: 405-8.
66 Sehnert W, Hackenberg K, Bierfert E. Fibri-nolysetherapie bei Cumarinnekrosen. Dtsch Med Wochenschr 1982; 107: 515-9.
67 Stamm H. Antikoagulantien-Nekrosen. Fortschr Geburtsh Gynäkol 1969; 39: 57-60.
68 Terres W, Lund GK, Hübner A. et al. Endogenous tissue plasminogen activator and platelet reactivity as risk factors for reocclusion after recanalization of chronic total coronary occlusions. Am Heart J 1995; 130: 711-6.
69 Theiss W. Thrombolysetherapie tiefer Venenthrombosen. Indikationsstellung, Behandlungsverfahren. Internist 1992; 33: 225-31.
70 Theroux P, Perez-Villa F, Waters D. et al. Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 1995; 91: 2132-9.
71 US Pharmacopeia, 20th rev, US Pharmaco-peial Convention, Rockville, MD. 1980: 686
72 Van den Besselaar AMHP. The significance of the international normalized ratio (INR) for oral anticoagulant therapy. JIFCC 1991; 3: 146-51.
73 Wankmüller H, Ellbrück D, Seifried E. Pathophysiologie, Klinik und Therapie der Cumarin-Nekrose. Dtsch Med Wochenschr 1991; 116: 1322-30.
74 Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. Prog Hemost Thromb 1991; 10: 1-34.
75 Warkentin TE, Levine MN, Roberts RS. et al. Heparin-induced thrombocytopenia is more common with unfractionated heparin than with low molecular weight heparin. Thromb Haemost 1993; 69: 911-7.
76 Warkentin TE, Levine MN, Hirsh J. et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5.
77 Wehmeier A, Schneider W. Thrombozyten-funktionshemmung als therapeutisches Prinzip. Inn Med 1985; 12: 187-95.
78 White RH, Mc Curdy SA, von Marensdorff H. et al. Home prothrombin time monitoring after the initiation of warfarin therapy. A randomised prospective study. Ann Intern Med 1989; 111: 730-7.